Human Proprotein Convertase 9 /PCSK9 Standard (人前蛋白转化酶枯草溶菌素 (PCSK9) 标准品)
¥280.00
因产品会迭代升级,具体实验步骤请按纸质版说明书操作
描述
文章目录[隐藏]
本产品只包含标准品试剂,如需购买试剂盒请点击下图
-
- EK1124
- ELISA试剂盒
Human Proprotein Convertase 9/PCSK9 ELISA Kit检测试剂盒(酶联免疫吸附法)
- ¥1,600.00 – ¥2,650.00
商品名 |
Human Proprotein Convertase 9 /PCSK9 Standard (人前蛋白转化酶枯草溶菌素 (PCSK9) 标准品) |
---|---|
组分 |
人PCSK9 标准品 |
检测方法 |
双抗夹心法 |
样本类型 |
血清,血浆,细胞培养上清及其他生物学样本 |
板式 |
管 |
保存 |
短期4℃,长期-20℃保存 |
运输条件 |
4℃蓝冰运输 |
检测原理:本试剂盒采用双抗体夹心酶联免疫吸附检测技术。特异性抗人PCSK9抗体预包被在高亲和力的酶标板上。酶标板孔中加入标准品、待测样本和生物素化的检测抗体,经过孵育,样本中存在的PCSK9与固相抗体和检测抗体结合。洗涤去除未结合的物质后,加入辣根过氧化物酶标记的链霉亲和素(Streptavidin-HRP)。洗涤后,加入显色底物TMB,避光显色。颜色反应的深浅与样本中PCSK9的浓度成正比。加入终止液终止反应,在450 nm波长(参考波长570 - 630 nm)测定吸光度值。
分子信息
PCSK9 分子靶点信息概述
- 分子名:PCSK9, proprotein convertase subtilisin/kexin type 9
- 基因家族:Proprotein convertase subtilisin/kexin family
- 别名:NARC-1; FH3
- 曾用名:HCHOLA3
- 全称:hypercholesterolemia, autosomal dominant 3
PCSK9 分子靶点综述
前蛋白转化酶枯草溶菌素(PCSK9)是分泌型枯草杆菌蛋白酶家族的蛋白酶K亚家族成员。它在内质网中进行分子内自催化加工,以可溶性酶原形式被合成。PCSK9与低密度脂蛋白(LDL)胆固醇受体结合,诱导LDLR降解。PCSK9变异可降低或升高循环的胆固醇。其它的变异与非常罕见的常染色体显性遗传的家族性高胆固醇血症(HCHOLA3)有关。突变增强了其蛋白酶活性,降低LDLR水平,阻止细胞吸收胆固醇。
人 Human PCSK9 分子靶点信息
- 分子名:PCSK9, proprotein convertase subtilisin/kexin type 9
- 别称:
- convertase subtilisin/kexin type 9 preproprotein
- FH3
- FHCL3
- HCHOLA3
- LDLCQ1
- NARC-1
- NARC1
- neural apoptosis regulated convertase 1
- neural apoptosis-regulated convertase 1
- PC9
- proprotein convertase 9
- subtilisin/kexin-like protease PC9
- 基因序列:NCBI_Gene: 255738
- 蛋白序列:UniProtKB: Q8NBP7
人 Human PCSK9靶点分子功能(预测)
Enables several functions, including lipoprotein particle receptor binding activity; serine-type endopeptidase activity; and sodium channel inhibitor activity. Involved in several processes, including cholesterol homeostasis; low-density lipoprotein particle receptor catabolic process; and regulation of receptor-mediated endocytosis. Located in several cellular components, including Golgi apparatus; endosome; and perinuclear region of cytoplasm. Part of PCSK9-AnxA2 complex and PCSK9-LDLR complex. Implicated in familial hypercholesterolemia and hypobetalipoproteinemia.
操作步骤
文章目录[隐藏]
- ELISA操作常见问题
- 血清OR血浆,哪个是ELISA的菜 
- ELISA通关必备丨数据篇丨标准曲线不佳 
- ELISA通关必备丨操作篇丨常见问题及解决方案 
- ELISA通关必备丨操作篇丨溶解与稀释标准品 
- ELISA通关必备丨样本篇丨不常见样本 
- ELISA通关必备丨样本篇丨常见样本丨细胞 
- ELISA通关必备丨如何选择试剂盒 
- ELISA通关必备丨基础知识 
- 真?假?ELISA试剂盒选择要小心 
- ELISA常见类型一 | 双抗夹心法,你要的都在这里! 
- ELISA常见类型二 | 竞争法,五分钟搞定! 
- 叮!联科向您投递了个ELISA实验操作干货包,请查收~ 
- 【视频】ELISA实验操作步骤演示视频教程 
- ELISA 组织样本的处理—大鼠组织 
- 【视频】ELISA实验原理与常见问题分析 
- 查看更多ELISA操作相关问题
ELISA操作常见问题
查看更多ELISA操作相关问题
引用文献
文章目录[隐藏]
- Activation of estrogen receptor α (ERα) is required for Alisol B23-acetate to prevent post-menopausal atherosclerosis and reduced lipid accumulation 
- Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle 
- Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women 
- Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle 
- Activation of estrogen receptor α (ERα) is required for Alisol B23-acetate to prevent post-menopausal atherosclerosis and reduced lipid accumulation 
Activation of estrogen receptor α (ERα) is required for Alisol B23-acetate to prevent post-menopausal atherosclerosis and reduced lipid accumulation 
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle 
Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women 
- 血清
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle 
- 细胞培养上清 血清
Activation of estrogen receptor α (ERα) is required for Alisol B23-acetate to prevent post-menopausal atherosclerosis and reduced lipid accumulation 
评价
目前还没有评价